Clinical trial · Interventional
Fixed Dose Rate Gemcitabine and Cisplatin Followed by Chemoradiation for Locally Advanced Pancreatic Cancer
Phase Ⅱ Trial of Fixed Dose Rate Gemcitabine and Cisplatin Chemotherapy Followed by Chemoradiation With Capecitabine in Patients With Locally Advanced Pancreatic Cancer
NCT01396668CI-TRIAL-00005225completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a phase Ⅱ trial of fixed dose rate gemcitabine and cisplatin chemotherapy followed by chemoradiation with capecitabine in patients with locally advanced pancreatic cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| gemcitabine, cisplatin, capecitabine | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Time to progression
- timeFrame
- 12 months
Secondary outcomes (5)
- measure
- safety
- timeFrame
- 12 months
- description
- number of patients who experienced grade 3-4 toxicity by NCI-CTCAE
- measure
- 1 year survival rate
- timeFrame
- 1 year
- measure
- response rate
- timeFrame
- 1 year
- description
- response rate by RECIST criteria
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * unresectable locally advanced pancreatic cancer * no distant metastasis * histologically confirmed adenocarcinoma of pancreas * 18-75 of age * ECOG performance status 0-2 * normal marrow function : * WBC at least 3,000/mm3 OR Absolute neutrophil count at least 1,500/mm3 * Platelet count at least 100,000/mm3 * normal liver function : --Bilirubin no greater than 2.0 mg/dL AST less than 3 times upper limit of normal (ULN) * normal renal function : --Creatinine no greater than 1.5 times ULN * signed informed consent
References
Publications (0)
Data not yet available
No reference posted for this study.